fda warns against compounded semaglutide about versions of popular weight loss drugs FDA Warns Against Using Compounded

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased slightly from September to December 2025 (+5.0%)

J Biol Chem 2003;278:25738-44

Some of the most well-known include: Semaglutide (Ozempic, Wegovy): Approved for both diabetes management and weight loss

Lifestyle interventions remain the primary approach to managing obesity, with medical therapy considered a secondary option, often used in conjunction with lifestyle modifications

A 2018 review in the International Journal of Molecular Sciences analyzed gene data showing GHK-Cus ability to reset genes to a healthier state, promoting anti-cancer, anti-inflammatory, and tissue-remodeling actions